BIOGEN INC. — Director's Dealing 2022

Dec 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2022-12-01

Reporting Person: Viehbacher Christopher (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-01	Stock Option	$301.85	A	80522	Acquired	2032-12-01	Common Stock (80522)	Direct
2022-12-01	Restricted Stock Unit	$	A	7040	Acquired		Common Stock (7040)	Direct
2022-12-01	Performance Stock Unit	$	A	45998	Acquired		Common Stock (45998)	Direct

Footnotes

F1: The Stock Options are eligible to vest and become exercisable in approximately equal annual installments on the first, second and third anniversaries of the grant date of December 1, 2022.

F2: Each Performance Stock Unit ("PSU") or Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock.

F3: Each RSU is eligible to vest on the third anniversary of the grant date of December 1, 2022.

F4: This represents the reporting person's PSUs that will be eligible for vesting based on achievement of absolute stock price compound annual growth rate goals ("Absolute CAGR PSUs") over a three-year performance period ending on November 30, 2025. The number of Absolute CAGR PSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.